Sunday, October 19, 2025

Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy

Authors: Tamara Castillo-Trivino, Ellen M. Mowry, Alberto Gajofatto, Dorothee Chabas, Elizabeth Crabtree-Hartman, Bruce A. Cree, Douglas S. Goodin, Ari J. Green, Darin T. Okuda, Daniel Pelletier, Scott S. Zamvil, Eric Vittinghoff, Emmanuelle Waubant

DOI: 10.1371/journal.pone.0016664

Abstract Summary

Patients with multiple sclerosis experiencing breakthrough disease on first-line therapy showed significant improvement after switching treatments. Those who switched to natalizumab reduced relapses by 70%, while immunosuppressant switchers saw a 77% reduction. Patients who didn’t switch showed no improvement, confirming that escalating therapy effectively controls disease activity in this challenging population.

Why Brain? 🧠

Switching MS patients with breakthrough disease to natalizumab or immunosuppressants reduces relapse rates by 68-76% compared to non-switchers, supporting escalation to second-line therapies.


The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.

share this recipe:
Facebook
X
Email
Print

Still hungry? Here’s more